Blood Test Measuring Telomeres to Help Detect Lung Cancer
Tests a blood marker for spotting lung cancer in adults, with and without the disease.
Plain-language title generated from the registry record
Registry title: Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
Key facts
- Where
- Barcelona, Elche, Madrid, Oviedo, Santander, Toledo, and Valencia, SpainSee the 12 sites
Where in Spain
- Hospital del MarBarcelona, SpainTaking people
- Institut Catalá D'Oncologia Badalona (ICO)Barcelona, SpainTaking people
- Hospital General Universitario de ElcheElche, SpainTaking people
- Clinica Universidad de NavarraMadrid, SpainTaking people
- HM Sanchinarro/CIOCCMadrid, SpainTaking people
- Hospital Universitario 12 OctubreMadrid, SpainTaking people
- Hospital Universitario Clínico San CarlosMadrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario Central De AsturiasOviedo, SpainTaking people
- Hospital Universitario Marqués de ValdecillaSantander, SpainTaking people
- Complejo Hospitalario de ToledoToledo, SpainTaking people
- Hospital Universitari i Politécnic La FeValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)
- Trial code
- NCT07465848
- Record updated
- 12 March 2026
- Original description
This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.Read full original descriptionShow less
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.
Inclusion: Case Group:; Person aged 45 years or older at the time of signing the consent form; Person with a current anatomopathologically confirmed diagnosis of small-cell or non-small cell lung cancer; Not having received any oncological treatment prior to sample collection (surgery, radiotherapy, or systemic treatment with chemotherapy or immunotherapy); Control Group:; Cohort A (High risk controls):; Person aged 45 years or older at the time of signing the consent form; High risk of lung cancer, defined as having a smoking history of at least 20 pack-year and currently smoking or having quit within the past 15 years; No diagnosis or suspicion of lung cancer. Asymptomatic individuals who have undergone a chest computed tomography (CT) scan for lung cancer screening within the 12 months prior to signing the informed consent and as part of routine clinical practice, with a LUNG-RADS score of 3 or lower, will be included; Cohort B (Low-risk controls):; Person aged 45 years or older at the time of signing the consent form; Without high risk of lung cancer according to the criteria defined in cohort A; No diagnosis or suspicion of lung cancer.
Exclusion: Patient who has undergone a biopsy or any invasive procedure or minor surgery less than 48 hours ago; Patient who has undergone major surgery less than 7 days ago; History of any malignant neoplasm, except for subjects with tumors in localized stages who have undergone radical treatment and have been disease-free for at least five years; Patient diagnosed with lung cancer who has already started oncological treatment before sample collection; Patient with severe chronic kidney disease, defined as a glomerular filtration rate below 15 ml/min; Patient with severe liver disease, defined as Child-Pugh C; Active infection, or treated less than 4 weeks ago; Vulnerable population, for example, minors, prisoners, pregnant women, adults physically or mentally incapable of giving consent.